Home
Resources
Publications
Thromboembolic Complications Following Aminocaproic Acid Use in Patients With Hematologic Malignancies

Thromboembolic Complications Following Aminocaproic Acid Use in Patients With Hematologic Malignancies

Rebecca C Juhl, Julianna V F Roddy, Tzu-Fei Wang, Junan Li, Jessica L Elefritz

Leuk Lymphoma. 2018 Oct;59(10):2377-2382.

PMID: 29424601

Abstract:

Aminocaproic acid is frequently used in patients with hematologic malignancy that present with thrombocytopenia with or without hemorrhage. We conducted a retrospective study to evaluate the safety of aminocaproic acid in 109 patients with hematologic malignancies. Patients were included if aminocaproic acid had been administered for at least 24 hours for the prevention or treatment of thrombocytopenic hemorrhage. Our primary outcome was thromboembolic complications defined as arterial or venous thrombotic events objectively confirmed by imaging studies. Thromboembolic complications occurred in five patients (4.6%) and all were venous thromboses. Other than the underlying malignancy, these patients also had many concurrent risk factors including indwelling central venous catheters, which could have contributed to thromboses. In conclusion, in our population of patients with a variety of hematological malignancies, aminocaproic acid does not appear to be associated with a high incidence of thromboembolic complications.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP60322-A	Aminocaproic acid		60-32-2	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: